Abstract. Objective: To analyse survival of HIV-infected patients who developed cytomegalovirus (CMV) disease and to identify prognostic factors of their survival. Methods: Cases of CMV disease diagnosed in the Aquitaine Cohort of HIV-infected patients (n 4297) during the 1986±1996 period, were reviewed using standardised de®nitions. 
Introduction
Cytomegalovirus (CMV) infection is the most common cause of life-threatening opportunistic infections in HIV-infected patients [1, 2] . Early case management and more importantly, extended use of ecacious primary prophylaxis of most bacterial and parasitic opportunistic infections, may explain its increasing contribution in the natural history of HIV disease. Its increasing relative and absolute frequency, potential sequelae and impairment of survival make CMV disease one of the most feared clinical conditions in advanced HIV infection. Long-term survival of patients presenting CMV disease manifestations had not been frequently reported, although this may be due to major changes in management of HIV-infected patients in general [3±5] and of those with CMV disease [6±8] . It seems particularly important to document how CMV disease presentation and prognosis may evolve in patients on antiretroviral therapy [9±11]. We described a cohort of HIVinfected patients with a CMV disease and analysed factors contributing to their survival over a 12-year period.
Patients and methods

Study population
The Groupe d'EpideÂ miologie Clinique du SIDA en Aquitaine (GECSA) has initiated in 1987 a surveillance system of HIV infection, which allowed the creation of the Aquitaine Cohort [12] . Inclusion criteria were: HIV-1 infection con®rmed by a Western blot test, regardless of clinical stage, age of 13 years or more consulting in one of the 16 participating wards, and informed consent. Patients were followed up at least once every 6 months by one of the participating physicians. Standardised epidemiological, clinical, biological and therapeutic informations were collected during each outpatient visit or hospitalisation. HIV transmission categories, are those used in France [13] : homosexuals, intravenous drug users (IVDUs), homosexuals-IVDUs, haemophiliacs, heterosexuals, blood-recipients and other/unknown. The 1986 CDC clinical classi®cation of HIV infection was used as well as the CDC/WHO AIDS de®nition adopted in France in 1987 by the Direction GeÂ neÂ rale de la SanteÂ , revised in 1993 but excluding the CD4 lymphocyte count criteria [14] .
Data collection
We ®rst extracted from the database of the Aquitaine Cohort all diagnoses of CMV disease reported by the participating clinicians. Standardised de®nition criteria (see below) were used to validate retrospectively these cases by record review. In parallel, we surveyed all pathology and ophtalmology departments in the Bordeaux University Hospital, looking for additional cases.
Case de®nition
Diagnostic criteria varied according to the anatomic site of CMV disease. Retinitis had to be con®rmed by an ophtalmologist who performed fundoscopic examination. Digestive manifestations (mouth, oesophagus, stomach, duodenum, colon, rectum and pancreas) and hepatitis were histologically con®rmed by the identi®cation of intranuclear inclusions and/or the detection of CMV antigen using monoclonal antibodies. Cholangitis was a presumptive diagnosis based on the following criteria: chronic cholestasis, thickening of biliary ducts con®rmed by ultrasonography and intranuclear inclusions seen in biopsy specimens (duodenum or liver). Genital infection was diagnosed after identi®cation of intranuclear inclusions in genital specimens.
Encephalitis was con®rmed histologically by brain biopsy or autopsy. It was probable if (1) CMV was identi®ed by polymerase chain reaction or in situ hybridization in cerebro-spinal¯uid (CSF), or (2) symptoms (fever, confusion, psychomotor retardation) were reported in the context of recent CMV seroconversion and presence of anti-CMV antibody in the CSF. Diagnosis was considered possible if symptoms were reported and tomodensitometry or magnetic resonance imaging showed periventricular contrast enhancement.
Cytomegalovirus pneumonitis was con®rmed if (1) symptomatology (dyspnea, hypoxemia) and chest radiography abnormalities (interstitial shadowing) were recorded, (2) intranuclear inclusions were identi®ed on brushing or biopsy specimen, (3) the evolution was favourable under anti-CMV treatment, and (4) no other pathogen was identi®ed. Diagnosis was probable if the same criteria were veri®ed except the pathology ®ndings. [15] was used with a backward strategy to look for factors associated with survival among the following: age, gender, HIV transmission category, anatomic site of the CMV initial episode, CD4 lymphocyte count, CMV disease as the AIDS ®rst de®ning event, history of other AIDS de®ning events (infections, neoplasias and neurological manifestations). Protease inhibitor (PI) prescription and anti-CMV treatment were included in the proportional hazard model as time dependent covariates. Virological markers of CMV infection [16, 17] were too recently used in routine to be considered in this 12-year study.
Statistical analysis
STATA software, version 5.1 (STATA Corp., College Station, Texas) was used for statistical analysis.
Results
Description of the study sample
The study population consists of the 4297 subjects included in the Aquitaine Cohort and followed for an average of 58.6 months until 31 December 1996. The study sample is made of the 274 patients who presented at least one initial manifestation of CMV disease during the study period, yielding a cumulative incidence of 6.4%. During the same period, the cumulative incidence of Pneumocystis carinii infection was 12.6%; it was 11.7% for toxoplasmosis infection, 11.0% for candidiasis, 7.6% for mycobacterium avium complex disease (MAC) and 6.3% for tuberculosis. The detailed description of the cases diagnosed until 1994 has been published elsewhere [18] , as well as the analysis of the predictive factors of occurrence of CMV disease in the Cohort [19] . Among the 274 patients of the study sample, 253 records were used for survival analysis, as ®ve had no follow-up data and 16 patients had no lymphocyte count available at the time of the diagnosis of CMV disease. Patients included did not dier from others according to baseline characteristics available.
The mean age (n 253) was 39.4 years, the male to female sex-ratio 4.3:1; 55.3% of the patients had acquired their HIV infection through homosexual contacts, 19.0% were intravenous drug users, 17.0% heterosexuals, 6.3% haemophiliacs or blood recipients and transmission category was not documented for 2.4%. CMV disease was the ®rst manifestation of AIDS in 29.2% of the cases. A neurological AIDS de®ning event was present at the time of CMV disease diagnosis or in the patients' history in 10.7% of the cases, neoplasia in 28.8% and another opportunistic infection in 60.0%. The median CD4 lymphocyte count was 14/mm 3 (interquartile range: 4±36/mm 3 ). The 253 patients studied presented 268 initial clinical manifestations of CMV disease. Retinitis accounted for 68.4% of the anatomic sites involved (Table 1a) . Fifteen patients (5.9%) presented simultaneously two CMV disease manifestations. Among them, 13 (86.6%) had a retinitis associated to digestive tract infection (®ve cases), encephalitis (six cases) and pneumonia (two cases). Two patients presented a pneumonia associated with digestive tract infection. Those infections were certain for 89.2% of cases (Table 1b) . Nine percent were considered as probable diagnoses (19 pneumonia, ®ve encephalitis) and 1.9% as possible (four cases of encephalitis). Laboratory data were used for the diagnosis of the ®ve probable cases of encephalitis. In half of the patients, at least one other opportunistic infection was diagnosed at the same time as CMV disease (Table 1c) , the most frequent being candidiasis (n 54), followed by toxoplasmosis (n 29) and Pneumocystis carinii infection (n 26). Tuberculosis occurred in seven cases. Other infections were: cryptosporidiosis/microsporidiosis (n 11), herpes zoster (n 7), herpetic infection (n 6), septicaemia (n 6), progressive multifocal leukoencephalopathy (n 4), cryptococcosis (n 4), oral leucoplasia (n 2), salmonella infection (n 1), isosporiasis (n 1), lambliasis (n 1) and Pseudomonas pneumonia (n 1). Only 4% of the other opportunistic infections were diagnosed in the same anatomic site as CMV disease. Anti-CMV disease treatment (ganciclovir, foscarnet or more recently, cidofovir) was reported in 135 patients (53.3%) immediately after this diagnosis and in 138 patients (54.6%) at dierent times during their follow-up. Most of the patients who were not treated were diagnosed before 1992 (Table 1a) ; half of them were poorly followed up, generally less than once in 3 months after the diagnosis of CMV disease. Only one out of the 70 patients diagnosed in 1995±1996 did not receive treatment. He was followed up for 1 year after the diagnosis of other AIDS manifestations, then CMV infection was diagnosed and he deceased 1 month later. CMV disease of the digestive tract, of`other' anatomic sites and CMV pneumonia were the least frequently treated cases in 13.6, 37.5 and 36.4% respectively (p < 0.001). Those subjects who were already at AIDS stage when they developed CMV disease and who had a history of opportunistic infection and less than 100 CD4/mm 3 were more likely to be treated for their CMV disease than the others, with treatment rates of 57.5 versus 41.9% for patients without previous AIDS de®ning event (p 0.03), 61.2 versus 39.6% in the absence of history of opportunistic infections (p 0.001) and 56.7 versus 13.6% for patients with a CD4+ cell count P100 cells/mm 3 (p < 0.0001), respectively.
The proportion of patients treated with antiretrovirals (reverse transcriptase and/or protease inhibitors) at the time of diagnosis of CMV disease was 51.0% (n 130); it was 36.2% for those patients diagnosed with CMV disease before 1992, 53.4% between 1992 and 1994, and 65.7% in 1995± 1996. For the latter period, 28.6% of the patients received monotherapy, 20.0% a dual therapy and 17.1% a triple or quadruple therapy. Patients with retinitis were more often under antiretroviral treatment than the others (57.2 versus 38.8%; p 0.006). Thirteen (5.1%) patients were treated by protease inhibitor (PI) at the time of their CMV diagnosis and 35 (13.8%) at dierent times during their follow-up.
Survival analysis
The case fatality ratio was high in this series as 221 (87.3%) of the 253 patients had died as on 31 December 1997. The median survival time after the diagnosis of CMV disease was 6.8 months (Figure 1) . Thus, the probability of death due to CMV disease was 45.7% (95% con®dence interval [CI]: 39.8± 52.1%) 6 months after the initial diagnosis, 71.5% after 1 year (CI: 65.7±77.0%), and 80.8% after 18 months (CI: 75.6±85.5%). Table 2 describes survival according to the main prognostic factors studied. In the univariate analysis, the probability of death did not dier according to gender, HIV transmission category, the history or the presence of another opportunistic infection or another neurological AIDS manifestation. Patients with CMV-encephalitis or multiple anatomic sites involved were more likely to die than others. Multivariate analysis including PI prescription and CMV disease treatment as time dependent covariates showed the same associations for the variables already described (Table 3 ). 
Discussion
This study, conducted between 1986 and 1997 on a population of 4297 HIV-1 infected patients in SouthWest of France, has allowed to identify 274 subjects with an initial clinical manifestation of CMV disease, a large study sample selected after medical validation with standardised clinical and paraclinical criteria. Case de®nition used in this work was developed to cover thoroughly systemic clinical manifestations of CMV disease. It could not take into account CMV infection hidden in clinically inaccessible organs such as the adrenal glands. Cross-checking our sources of information has allowed us to include patients from the Aquitaine Cohort, who had developed a CMV disease manifestation non-spontaneously reported by clinicians. Under-reporting bias was thus minimised. The cumulative incidence of CMV disease in the Aquitaine Cohort was estimated at 6.4% over this period, an estimate comparable to the literature [20] .
The 253 patients included in our ®nal study sample experienced a short survival after their initial CMV disease diagnosis. This length of survival was included in the time interval usually described in samples of HIV infected subjects with CMV disease. In other studies, survival was studied either in speci®c groups presenting only certain localisations like CMV retinitis [21] with longer survival, or in patients already at the AIDS stage [22] , with shorter survival. The length of survival with CMV disease was similar to that in patients with MAC [23] or toxoplasmosis [24] , but a little longer than in those with the diagnosis of Pneumocystis carinii pneumonia [25] .
Univariate analysis showed a relation between the end organ aected by CMV disease and patients' survival as in previous reports [26±28]. We found that disseminated disease and encephalitis were associated with the worst prognosis. Patients who presented a pneumonia had a longer survival than previously described [29] , but only 18 cases of isolated pneumonia were documented in this sample. Moreover, in the 15 patients presenting a disseminated disease, four had pneumonia and had a particularly short survival. Multivariate analysis con®rmed the bad prognosis of disseminated CMV infection, in comparison to CMV retinitis, but it did not show speci®c in¯uence of other CMV disease anatomic sites on survival. Almost 4% of CMV disease occurred simultaneously with at least one other opportunistic infection in the same anatomic site. In those cases and more particularly for the ®ve cases for whom CMV diagnosis was probable, it is dicult to know if CMV is not simply a bystander opportunist. The same question could be asked for 17 cases (6.7%) associating CMV disease and disseminated MAC disease.
In multivariate analysis, neither association with neurological AIDS de®ning event, nor with other AIDS de®ning opportunistic infections had a prognostic role. CMV disease is known to be independently associated with the risk of death [19] as well as MAC, toxoplasmosis and Pneumocystis carinii pneumonia [30, 31] . Although we had a high proportion of associated opportunistic infections, there were too few cases of CMV and other opportunistic infection to allow individual analyses. On the other hand, past or present AIDS de®ning malignancy was associated with a shorter survival and 30% of the patients of this sample had a neoplasia.
The prognostic value of CD4 cell count is con®rmed by multivariate analysis. HIV-RNA Our study showed the evolution of therapeutic management of CMV disease. Only one patient did not receive speci®c treatment at diagnosis of CMV disease after 1994 whereas before 1992, 89% were not treated. Some end organ speci®c diseases were less often treated than others, for instance pneumonia, pancreatitis, genital or medullar infection. However, this can be explained by the fact that their diagnosis is quite dicult and often delayed. Retrospective validation of CMV disease diagnosis using pathology data permitted us to include those cases in our study. Multivariate analysis showed the trend of treating CMV disease, regardless of the drug regimen used as it has been already described [32, 33] . Diversity of anti-CMV treatments permits a better adaptation to patients, needs. Foscarnet was often used in our series. This drug is known for its capacity to reduce HIV replication [34] . These facts could explain in part the demonstrated impact of anti-CMV treatment on survival [35] .
Antiretroviral treatment has considerably changed during the follow-up of our study [36] . This is reected in the increasing proportion of patients treated with at least one antiretroviral drug during the observation period. The proportion of patients who were prescribed two or more antiretroviral drugs signi®cantly increased during the last 2 years. Randomised trials have shown survival improvement under Highly Active Antiretroviral Treatment (HAART) including PI [37] . In our study as in the recent report by Walsh et al. [38] , PI prescription improved the survival of HIV-infected patients with CMV disease. This result is independent of the anatomic site involved, the baseline CD4 cell count level, the past or present malignancy associated, or the CMV treatment used at any time during the followup. In our study, we noted the eect of HAART with PI, even in the case of patients with advanced HIV infection. This result could be a consequence of direct [39] and indirect eect of PI [40] .
In conclusion, survival time in HIV-infected patients with CMV disease was short in the Aquitaine Cohort and was in¯uenced by ®ve factors over the 12-year period. Past or present malignancy and disseminated CMV disease were pejorative factors. A higher baseline CD4 cell count as well as anti-CMV treatment, and above all, PI prescription at any time during the follow-up were associated with a better survival rate.
As the incidence of CMV infection and recurrence is reduced after a certain duration of PI treatment [41] , there may be some optimism that CMV disease which aected the prognosis and quality of life of so many HIV-infected patients until recently, will become less frequent and life threatening. Financial support was provided by The French National AIDS Research Agency (ANRS) through its Coordinated Action no 7.
